Neuropharmacology of 3,4-Methylenedioxypyrovalerone (MDPV), Its Metabolites, and Related Analogs

  • Michael H. Baumann
  • Mohammad O. Bukhari
  • Kurt R. Lehner
  • Sebastien Anizan
  • Kenner C. Rice
  • Marta Concheiro
  • Marilyn A. Huestis
Chapter

Abstract

3,4-Methylenedioxypyrovalerone (MDPV) is a psychoactive component of so-called bath salts products that has caused serious medical consequences in humans. In this chapter, we review the neuropharmacology of MDPV and related analogs, and supplement the discussion with new results from our preclinical experiments. MDPV acts as a potent uptake inhibitor at plasma membrane transporters for dopamine (DAT) and norepinephrine (NET) in nervous tissue. The MDPV formulation in bath salts is a racemic mixture, and the S isomer is much more potent than the R isomer at blocking DAT and producing abuse-related effects. Elevations in brain extracellular dopamine produced by MDPV are likely to underlie its locomotor stimulant and addictive properties. MDPV displays rapid pharmacokinetics when injected into rats (0.5–2.0 mg/kg), with peak plasma concentrations achieved by 10–20 min and declining quickly thereafter. MDPV is metabolized to 3,4-dihydroxypyrovalerone (3,4-catechol-PV) and 4-hydroxy-3-methoxypyrovalerone (4-OH-3-MeO-PV) in vivo, but motor activation produced by the drug is positively correlated with plasma concentrations of parent drug and not its metabolites. 3,4-Catechol-PV is a potent uptake blocker at DAT in vitro but has little activity after administration in vivo. 4-OH-3-MeO-PV is the main MDPV metabolite but is weak at DAT and NET. MDPV analogs, such as α-pyrrolidinovalerophenone (α-PVP), display similar ability to inhibit DAT and increase extracellular dopamine concentrations. Taken together, these findings demonstrate that MDPV and its analogs represent a unique class of transporter inhibitors with a high propensity for abuse and addiction.

Keywords

Addiction Dopamine MDPV Pyrrolidinophenones Synthetic cathinones Transporter Uptake α-PVP 

References

  1. 1.
    Baumann MH, Solis E Jr, Watterson LR, Marusich JA, Fantegrossi WE, Wiley JL (2014) Baths salts, spice, and related designer drugs: the science behind the headlines. J Neurosci 34:15150–151158PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Madras BK (2016) The growing problem of new psychoactive substances (NPS). Curr Top Behav Neurosci (in press)Google Scholar
  3. 3.
    Zawilska JB, Andrzejczak D (2015) Next generation of novel psychoactive substances on the horizon – a complex problem to face. Drug Alcohol Depend 157:1–17PubMedCrossRefGoogle Scholar
  4. 4.
    Baumann MH, Volkow ND (2016) Abuse of new psychoactive substances: threats and solutions. Neuropsychopharmacology 41:663–665PubMedCrossRefGoogle Scholar
  5. 5.
    Brandt SD, King LA, Evans-Brown M (2014) The new drug phenomenon. Drug Test Anal 6:587–597PubMedCrossRefGoogle Scholar
  6. 6.
    Drug Enforcement Administration, Office of Diversion Control (2014) Special report: synthetic cannabinoids and cathinones reported in NFLIS, 2010–2013. http://www.deadiversion.usdoj.gov/nflis/spec_rpt_CathCan_2013.pdf
  7. 7.
    Shanks KG, Dahn T, Behonick G, Terrell A (2012) Analysis of first and second generation legal highs for synthetic cannabinoids and synthetic stimulants by ultra-performance liquid chromatography and time of flight mass spectrometry. J Anal Toxicol 36:360–371PubMedCrossRefGoogle Scholar
  8. 8.
    United Nations Office of Drugs and Crime. World Drug Report (2015). http://www.unodc.org/documents/wdr2015/World_Drug_Report_2015.pdf
  9. 9.
    Prosser JM, Nelson LS (2012) The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol 8:33–34PubMedCrossRefGoogle Scholar
  10. 10.
    Centers for Disease Control and Prevention (CDC) (2011) Emergency department visits after use of a drug sold as “bath salts”--Michigan, November 13, 2010-March 31, 2011. MMWR Morb Mortal Wkly Rep 60:624–627Google Scholar
  11. 11.
    Murphy CM, Dulaney AR, Beuhler MC, Kacinko S (2013) “Bath salts” and “plant food” products: the experience of one regional US poison center. J Med Toxicol 9:42–48PubMedCrossRefGoogle Scholar
  12. 12.
    Spiller HA, Ryan ML, Weston RG, Jansen J (2011) Clinical experience with and analytical confirmation of “bath salts” and “legal highs” (synthetic cathinones) in United States. Clin Toxicol (Phila) 49:499–505CrossRefGoogle Scholar
  13. 13.
    Ross EA, Reisfield GM, Watson MC, Chronister CW, Goldberger BA (2012) Psychoactive “bath salts” intoxication with methylenedioxypyrovalerone. Am J Med 125:854–858PubMedCrossRefGoogle Scholar
  14. 14.
    Kesha K, Boggs CL, Ripple MG, Allan CH, Levine B, Jufer-Phipps R, Doyon S, Chi P, Fowler DR (2013) Methylenedioxypyrovalerone (“bath salts”), related death: case report and review of the literature. J Forensic Sci 58:1654–1659PubMedCrossRefGoogle Scholar
  15. 15.
    Penders TM, Gestring RE, Vilensky DA (2012) Intoxication delirium following use of synthetic cathinone derivatives. Am J Drug Alcohol Abuse 38:616–617PubMedCrossRefGoogle Scholar
  16. 16.
    Drug Enforcement Administration (2013) Establishment of drug codes for 26 substances. Final rule. Fed Regist 78:664–666Google Scholar
  17. 17.
    Marinetti LJ, Antonides HM (2013) Analysis of synthetic cathinones commonly found in bath salts in human performance and postmortem toxicology: method development, drug distribution and interpretation of results. J Anal Toxicol 37:135–146PubMedCrossRefGoogle Scholar
  18. 18.
    Karch SB (2015) Cathinone neurotoxicity (The “3Ms”). Curr Neuropharmacol 13:21–25PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Froberg BA, Levine M, Beuhler MC, Judge BS, Moore PW, Engebretsen KM, Mckeown NJ, Rosenbaum CD, Young AC, Rusyniak DE; ACMT Toxicology Investigators Consortium (ToxIC) (2015) Acute methylenedioxypyrovalerone toxicity. J Med Toxicol 11:185–194Google Scholar
  20. 20.
    European Monitoring Centre for Drugs and Drug Addiction (2014) EMCDDA–Europol Joint Report on a new psychoactive substance: MDPV (3,4-methylenedioxypyrovalerone). http://www.emcdda.europa.eu/system/files/publications/819/TDAS14001ENN_466653.pdf
  21. 21.
    Murray BL, Murphy CM, Beuhler MC (2012) Death following recreational use of designer drug “bath salts” containing 3,4-Methylenedioxypyrovalerone (MDPV). J Med Toxicol 8:69–75PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Wyman JF, Lavins ES, Engelhart D, Armstrong EJ, Snell KD, Boggs PD, Taylor SM, Norris RN, Miller FP (2013) Postmortem tissue distribution of MDPV following lethal intoxication by “bath salts”. J Anal Toxicol 37:182–185PubMedCrossRefGoogle Scholar
  23. 23.
    Baumann MH (2014) Awash in a sea of ‘bath salts’: implications for biomedical research and public health. Addiction 109:1577–1579PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Simmler LD, Liechti ME (2016) Interactions of cathinone NPS with human transporters and receptors in transfected cells. Curr Top Behav Neurosci (in press)Google Scholar
  25. 25.
    Kristensen AS, Andersen J, Jørgensen TN, Sørensen L, Eriksen J, Loland CJ, Strømgaard K, Gether U (2011) SLC6 neurotransmitter transporters: structure, function, and regulation. Pharmacol Rev 63:585–640PubMedCrossRefGoogle Scholar
  26. 26.
    Gorman JM, Kent JM (1999) SSRIs and SMRIs: broad spectrum of efficacy beyond major depression. J Clin Psychiatry 60(Suppl 4):33–38PubMedGoogle Scholar
  27. 27.
    Iversen L (2006) Neurotransmitter transporters and their impact on the development of psychopharmacology. Br J Pharmacol 147(Suppl1):S82–S88PubMedPubMedCentralGoogle Scholar
  28. 28.
    Howell LL, Kimmel HL (2008) Monoamine transporters and psychostimulant addiction. Biochem Pharmacol 75:196–217PubMedCrossRefGoogle Scholar
  29. 29.
    Rothman RB, Baumann MH (2003) Monoamine transporters and psychostimulant drugs. Eur J Pharmacol 479:23–40PubMedCrossRefGoogle Scholar
  30. 30.
    Reith ME, Blough BE, Hong WC, Jones KT, Schmitt KC, Baumann MH, Partilla JS, Rothman RB, Katz JL (2015) Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter. Drug Alcohol Depend 147:1–19PubMedCrossRefGoogle Scholar
  31. 31.
    Sitte HH, Freissmuth M (2015) Amphetamines, new psychoactive drugs and the monoamine transporter cycle. Trends Pharmacol Sci 36:41–50PubMedCrossRefGoogle Scholar
  32. 32.
    Angoa-Perez M, Anneken JH, Kuhn DM (2016) Neurotoxicology of synthetic cathinone analogs. Curr Top Behav Neurosci (in press)Google Scholar
  33. 33.
    Baumann MH, Wang X, Rothman RB (2007) 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology (Berl) 189:407–424CrossRefGoogle Scholar
  34. 34.
    Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR (2007) New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 47:681–698PubMedCrossRefGoogle Scholar
  35. 35.
    Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39:32–41PubMedCrossRefGoogle Scholar
  36. 36.
    Rothman RB, Vu N, Partilla JS, Roth BL, Hufeisen SJ, Compton-Toth BA, Birkes J, Young R, Glennon RA (2003) In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates. J Pharmacol Exp Ther 307:138–145PubMedCrossRefGoogle Scholar
  37. 37.
    Glennon RA, Yousif M, Naiman N, Kalix P (1987) Methcathinone: a new and potent amphetamine-like agent. Pharmacol Biochem Behav 26:547–551PubMedCrossRefGoogle Scholar
  38. 38.
    Kalix P, Glennon RA (1986) Further evidence for an amphetamine-like mechanism of action of the alkaloid cathinone. Biochem Pharmacol 35:3015–3019PubMedCrossRefGoogle Scholar
  39. 39.
    Cozzi NV, Sievert MK, Shulgin AT, Jacob P 3rd, Ruoho AE (1999) Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines. Eur J Pharmacol 381:63–69PubMedCrossRefGoogle Scholar
  40. 40.
    Nagai F, Nonaka R, Satoh Hisashi Kamimura K (2007) The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol 559:132–137PubMedCrossRefGoogle Scholar
  41. 41.
    Héron C, Costentin J, Bonnet JJ (1994) Evidence that pure uptake inhibitors including cocaine interact slowly with the dopamine neuronal carrier. Eur J Pharmacol 264:391–398PubMedCrossRefGoogle Scholar
  42. 42.
    Vaugeois JM, Bonnet JJ, Duterte-Boucher D, Costentin J (1993) In vivo occupancy of the striatal dopamine uptake complex by various inhibitors does not predict their effects on locomotion. Eur J Pharmacol 230:195–201PubMedCrossRefGoogle Scholar
  43. 43.
    Meltzer PC, Butler D, Deschamps JR, Madras BK (2006) 1(4-Methylphenyl)-2-pyrrolidin-1-yl-petan-1-one (pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem 49:1420–1432PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Hadlock GC, Webb KM, McFadden LM, Chu PW, Ellis JD, Allen SC, Andrenyak DM, Vieira-Brock PL, German CL, Conrad KM, Hoonakker AJ, Gibb JW, Wilkins DG, Hanson GR, Fleckenstein AE (2011) 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther 339:530–536PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    López-Arnau R, Martínez-Clemente J, Pubill D, Escubedo E, Camarasa J (2012) Comparative neuropharmacology of three psychostimulant cathinone derivatives: butylone, mephedrone and methylone. Br J Pharmacol 167:407–420PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Baumann MH, Ayestas MA Jr, Partilla JS, Sink JR, Shulgin AT, Daley PF, Brandt SD, Rothman RB, Ruoho AE, Cozzi NV (2012) The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 37:1192–1203PubMedCrossRefGoogle Scholar
  47. 47.
    Eshleman AJ, Wolfrum KM, Hatfield MG, Johnson RA, Murphy KV, Janowsky A (2013) Substituted methcathinones differ in transporter and receptor interactions. Biochem Pharmacol 85:1803–1815PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Simmler LD, Buser TA, Donzelli M, Schramm Y, Dieu LH, Huwyler J, Chaboz S, Hoener MC, Liechti ME (2013) Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 168:458–470PubMedCrossRefGoogle Scholar
  49. 49.
    Baumann MH, Partilla JS, Lehner KR, Thorndike EB, Hoffman AF, Holy M, Rothman RB, Goldberg SR, Lupica CR, Sitte HH, Brandt SD, Tella SR, Cozzi NV, Schindler CW (2013) Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive ‘bath salts’ products. Neuropsychopharmacology 38:552–562PubMedCrossRefGoogle Scholar
  50. 50.
    Kolanos R, Partilla JS, Baumann MH, Hutsell BA, Banks ML, Negus SS, Glennon RA (2015) Stereoselective actions of methylenedioxypyrovalerone (MDPV) to inhibit dopamine and norepinephrine transporters and facilitate intracranial self-stimulation in rats. ACS Chem Neurosci 6:771–777PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Marusich JA, Antonazzo KR, Wiley JL, Blough BE, Partilla JS, Baumann MH (2014) Pharmacology of novel synthetic stimulants structurally related to the “bath salts” constituent 3,4-methylenedioxypyrovalerone (MDPV). Neuropharmacology 87:206–213PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Kolanos R, Solis E Jr, Sakloth F, De Felice LJ, Glennon RA (2013) “Deconstruction” of the abused synthetic cathinone methylenedioxypyrovalerone (MDPV) and an examination of effects at the human dopamine transporter. ACS Chem Neurosci 4:1524–1529PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Cameron KN, Kolanos R, Solis E Jr, Glennon RA, De Felice LJ (2013) Bath salts components mephedrone and methylenedioxypyrovalerone (MDPV) act synergistically at the human dopamine transporter. Br J Pharmacol 168:1750–1757PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Suzuki M, Deschamps JR, Jacobson AE, Rice KC (2015) Chiral resolution and absolute configuration of the enantiomers of the psychoactive “designer drug” 3,4-methylenedioxypyrovalerone. Chirality 27:287–293PubMedCrossRefGoogle Scholar
  55. 55.
    Gannon BM, Williamson A, Suzuki M, Rice KC, Fantegrossi WE (2016) Stereoselective effects of abused “bath salt” constituent 3,4-methylenedioxypyrovalerone in mice: drug discrimination, locomotor activity, and thermoregulation. J Pharmacol Exp Ther 356:615–623PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Baumann MH, Clark RD, Woolverton WL, Wee S, Blough BE, Rothman RB (2011) In vivo effects of amphetamine analogs reveal evidence for serotonergic inhibition of mesolimbic dopamine transmission in the rat. J Pharmacol Exp Ther 337:218–2125PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Rothman RB, Blough BE, Woolverton WL, Anderson KG, Negus SS, Mello NK, Roth BL, Baumann MH (2005) Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration. J Pharmacol Exp Ther 313:1361–1369PubMedCrossRefGoogle Scholar
  58. 58.
    Ikemoto S (2007) Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex. Brain Res Rev 56:27–78PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Willuhn I, Wanat MJ, Clark JJ, Phillips PE (2010) Dopamine signaling in the nucleus accumbens of animals self-administering drugs of abuse. Curr Top Behav Neurosci 3:29–71PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Zolkowska D, Jain R, Rothman RB, Partilla JS, Roth BL, Setola V, Prisinzano TE, Baumann MH (2009) Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. J Pharmacol Exp Ther 329:738–746PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Cozzi NV, Brandt SD, Daley PF, Partilla JS, Rothman RB, Tulzer A, Sitte HH, Baumann MH (2013) Pharmacological examination of trifluoromethyl ring-substituted methcathinone analogs. Eur J Pharmacol 699:180–187PubMedCrossRefGoogle Scholar
  62. 62.
    Kehr J, Ichinose F, Yoshitake S, Goiny M, Sievertsson T, Nyberg F, Yoshitake T (2011) Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats. Br J Pharmacol 164:1949–1958PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Wright MJ Jr, Angrish D, Aarde SM, Barlow DJ, Buczynski MW, Creehan KM, Vandewater SA, Parsons LH, Houseknecht KL, Dickerson TJ, Taffe MA (2012) Effect of ambient temperature on the thermoregulatory and locomotor stimulant effects of 4-methylmethcathinone in Wistar and Sprague-Dawley rats. PLoS One 7, e44652PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Suyama JA, Sakloth F, Kolanos R, Glennon RA, Lazenka MF, Negus SS, Banks ML (2016) Abuse-related neurochemical effects of para-substituted methcathinone analogs in rats: microdialysis studies of nucleus accumbens dopamine and serotine. J Pharmacol Exp Ther 356:182–190PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Baumann MH, Clark RD, Franken FH, Rutter JJ, Rothman RB (2008) Tolerance to 3,4-methylenedioxymethamphetamine in rats exposed to single high-dose binges. Neuroscience 152:773–784PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Schindler CW, Thorndike EB, Goldberg SR, Lehner KR, Cozzi NV, Brandt SD, Baumann MH (2016) Reinforcing and neurochemical effects of the “bath salts” constituents 3,4-methylenedioxypyrovalerone (MDPV) and 3,4-methylenedioxy-N-methylcathinone (methylone) in male rats. Psychopharmacology (Berl) 233:1981–1990CrossRefGoogle Scholar
  67. 67.
    Glennon RA, Young R (2016) Neurobiology of 3,4-methylenedioxypyrovalerone (MDPV) and α-pyrrolidinovalerophenone (α-PVP). Brain Res Bull 126:111–126Google Scholar
  68. 68.
    Aarde SM, Huang PK, Creehan KM, Dickerson TJ, Taffe MA (2013) The novel recreational drug 3,4-methylenedioxypyrovalerone (MDPV) is a potent psychomotor stimulant: self-administration and locomotor activity in rats. Neuropharmacology 71:130–140PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Huang PK, Aarde SM, Angrish D, Houseknecht KL, Dickerson TJ, Taffe MA (2012) Contrasting effects of d-methamphetamine, 3,4-methylenedioxymethamphetamine, 3,4-methylenedioxypyrovalerone, and 4-methylmethcathinone on wheel activity in rats. Drug Alcohol Depend 126:168–175PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    Fantegrossi WE, Gannon BM, Zimmerman SM, Rice KC (2013) In vivo effects of abused ‘bath salt’ constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice: drug discrimination, thermoregulation, and locomotor activity. Neuropsychopharmacology 38:563–573PubMedCrossRefGoogle Scholar
  71. 71.
    Gatch MB, Taylor CM, Forster MJ (2013) Locomotor stimulant and discriminative stimulus effects of ‘bath salt’ cathinones. Behav Pharmacol 24:437–447PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Marusich JA, Grant KR, Blough BE, Wiley JL (2012) Effects of synthetic cathinones contained in “bath salts” on motor behavior and a functional observational battery in mice. Neurotoxicology 33:1305–1313PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Howell LL, Cunningham KA (2015) Serotonin 5-HT2 receptor interactions with dopamine function: implications for therapeutics in cocaine use disorder. Pharmacol Rev 67:176–1797PubMedPubMedCentralCrossRefGoogle Scholar
  74. 74.
    Watterson LR, Olive MF (2016) Reinforcing effects of cathinone NPS in the i.v. drug self-administration paradigm. Curr Top Behav Neurosci (in press)Google Scholar
  75. 75.
    Watterson LR, Watterson E, Olive MF (2013) Abuse liability of novel ‘legal high’ designer stimulants: evidence from animal models. Behav Pharmacol 24:341–355PubMedCrossRefGoogle Scholar
  76. 76.
    Aarde SM, Angrish D, Barlow DJ, Wright MJ Jr, Vandewater SA, Creehan KM, Houseknecht KL, Dickerson TJ, Taffe MA (2013) Mephedrone (4-methylmethcathinone) supports i.v. self-administration in Sprague-Dawley and Wistar rats. Addict Biol 18:786–799PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Motbey CP, Clemens KJ, Apetz N, Winstock AR, Ramsey J, Li KM, Wyatt N, Callaghan PD, Bowen MT, Cornish JL, McGregor IS (2013) High levels of i.v. mephedrone (4-methylmethcathinone) self-administration in rats: neural consequences and comparison with methamphetamine. J Psychopharmacol 27:823–836PubMedCrossRefGoogle Scholar
  78. 78.
    Creehan KM, Vandewater SA, Taffe MA (2015) I.v. self-administration of mephedrone, methylone and MDMA in female rats. Neuropharmacology 92:90–97PubMedPubMedCentralCrossRefGoogle Scholar
  79. 79.
    Vandewater SA, Creehan KM, Taffe MA (2015) I.v. self-administration of entactogen-class stimulants in male rats. Neuropharmacology 99:538–545PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Watterson LR, Hood L, Sewalia K, Tomek SE, Yahn S, Johnson CT, Wegner S, Blough BE, Marusich JA, Olive MF (2012) The reinforcing and rewarding effects of methylone, a synthetic cathinone commonly found in “bath salts”. J Addict Res Ther Suppl 9:002Google Scholar
  81. 81.
    Watterson LR, Burrows BT, Hernandez RD, Moore KN, Grabenauer M, Marusich JA, Olive MF (2014) Effects of α-pyrrolidinopentiophenone and 4-methyl-N-ethylcathinone, two synthetic cathinones commonly found in second-generation “bath salts,” on intracranial self-stimulation thresholds in rats. Int J Neuropsychopharmacol 18 pii:pyu014Google Scholar
  82. 82.
    Watterson LR, Kufahl PR, Nemirovsky NE, Sewalia K, Grabenauer M, Thomas BF, Marusich JA, Wegner S, Olive MF (2014) Potent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV). Addict Biol 19:165–174PubMedCrossRefGoogle Scholar
  83. 83.
    Bonano JS, Glennon RA, De Felice LJ, Banks ML, Negus SS (2014) Abuse-related and abuse-limiting effects of methcathinone and the synthetic “bath salts” cathinone analogs methylenedioxypyrovalerone (MDPV), methylone and mephedrone on intracranial self-stimulation in rats. Psychopharmacology (Berl) 231:199–207CrossRefGoogle Scholar
  84. 84.
    Tettey J, Crean C (2015) New psychoactive substances: catalysing a shift in forensic science practice? Philos Trans R Soc Lond B Biol Sci 370:20140265PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Ellefsen KN, Concherio M, Huestis MA (2016) Synthetic cathinone pharmacokinetics, analytical methods, and toxicological findings from human performance and postmortem cases. Drug Metab Rev 48:237–265PubMedCrossRefGoogle Scholar
  86. 86.
    Concheiro M, Castaneto M, Kronstrand R, Huestis MA (2015) Simultaneous determination of 40 novel psychoactive stimulants in urine by liquid chromatography-high resolution mass spectrometry and library matching. J Chromatogr A 1397:32–42PubMedPubMedCentralCrossRefGoogle Scholar
  87. 87.
    Favretto D, Pascali JP, Tagliaro F (2013) New challenges and innovation in forensic toxicology: focus on the “New Psychoactive Substances”. J Chromatogr A 1287:84–95PubMedCrossRefGoogle Scholar
  88. 88.
    Smith JP, Sutcliffe OB, Banks CE (2015) An overview of recent developments in the analytical detection of new psychoactive substances (NPSs). Analyst 140:4932–4948PubMedCrossRefGoogle Scholar
  89. 89.
    Castaneto MS, Wohlfarth A, Desrosiers NA, Hartman RL, Gorelick DA, Huestis MA (2015) Synthetic cannabinoids pharmacokinetics and detection methods in biological matrices. Drug Metab Rev 47:124–174PubMedCrossRefGoogle Scholar
  90. 90.
    Meyer MR, Maurer HH (2012) Current applications of high-resolution mass spectrometry in drug metabolism studies. Anal Bioanal Chem 403:1221–1231PubMedCrossRefGoogle Scholar
  91. 91.
    Kreth K, Kovar K, Schwab M, Zanger UM (2000) Identification of the human cytochromes P450 involved in the oxidative metabolism of “Ecstasy”-related designer drugs. Biochem Pharmacol 59:1563–1571PubMedCrossRefGoogle Scholar
  92. 92.
    Meyer MR, Peters FT, Maurer HH (2008) The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic 3,4-methylenedioxy-methamphetamine and its enantiomers. Drug Metab Dispos 36:2345–2354PubMedCrossRefGoogle Scholar
  93. 93.
    Tucker GT, Lennard MS, Ellis SW, Woods HF, Cho AK, Lin LY, Hiratsuka A, Schmitz DA, Chu TY (1994) The demethylenation of methylenedioxymethamphetamine (“ecstasy”) by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol 47:1151–1156PubMedCrossRefGoogle Scholar
  94. 94.
    Strano-Rossi S, Cadwallader AB, de la Torre X, Botrè F (2010) Toxicological determination and in vitro metabolism of the designer drug methylenedioxypyrovalerone (MDPV) by gas chromatography/mass spectrometry and liquid chromatography/quadrupole time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 24:2706–2714PubMedCrossRefGoogle Scholar
  95. 95.
    Meyer MR, Du P, Schuster F, Maurer HH (2010) Studies on the metabolism of the α-pyrrolidinophenone designer drug methylenedioxy-pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC-MS and LC-high-resolution MS and its detectability in urine by GC-MS. J Mass Spectrom 45:1426–1442PubMedCrossRefGoogle Scholar
  96. 96.
    Baumann MH, Zolkowska D, Kim I, Scheidweiler KB, Rothman RB, Huestis MA (2009) Effects of dose and route of administration on pharmacokinetics of 3,4-methylenedioxymethamphetamine in the rat. Drug Metab Dispos 37:2163–2170PubMedPubMedCentralCrossRefGoogle Scholar
  97. 97.
    Concheiro M, Baumann MH, Scheidweiler KB, Rothman RB, Marrone GF, Huestis MA (2014) Nonlinear pharmacokinetics of (+/-)3,4-methylenedioxymethamphetamine (MDMA) and its pharmacodynamic consequences in the rat. Drug Metab Dispos 42:119–125PubMedPubMedCentralCrossRefGoogle Scholar
  98. 98.
    Anizan S, Concheiro M, Lehner KR, Bukhari MO, Suzuki M, Rice KC, Baumann MH, Huestis MA (2016) Linear pharmacokinetics of 3,4-methylenedioxypyrovalerone (MDPV) and its metabolites in the rat: relationship to pharmacodynamic effects. Addict Biol 21:339–347PubMedCrossRefGoogle Scholar
  99. 99.
    Anizan S, Ellefsen K, Concheiro M, Suzuki M, Rice KC, Baumann MH, Huestis MA (2014) 3,4-Methylenedioxypyrovalerone (MDPV) and metabolites quantification in human and rat plasma by liquid chromatography-high resolution mass spectrometry. Anal Chim Acta 827:54–63PubMedPubMedCentralCrossRefGoogle Scholar
  100. 100.
    Delaforge M, Jaouen M, Bouille G (1999) Inhibitory metabolite complex formation of methylenedioxymethamphetamine with rat and human cytochrome P450. Particular involvement of CYP 2D. Environ Toxicol Pharmacol 7:153–158Google Scholar
  101. 101.
    Heydari A, Yeo KR, Lennard MS, Ellis SW, Tucker GT, Rostami-Hodjegan A (2004) Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine. Drug Metab Dispos 32:1213–1217PubMedCrossRefGoogle Scholar
  102. 102.
    Chu T, Kumagai Y, DiStefano EW, Cho AK (1996) Disposition of methylenedioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion. Biochem Pharmacol 51:789–796PubMedCrossRefGoogle Scholar
  103. 103.
    de la Torre R, Farré M, Ortuño J, Mas M, Brenneisen R, Roset PN, Segura J, Camí J (2000) Non-linear pharmacokinetics of MDMA (‘ecstasy’) in humans. Br J Clin Pharmacol 49:104–109PubMedPubMedCentralCrossRefGoogle Scholar
  104. 104.
    Dinger J, Meyer MR, Maurer HH (2016) In vitro cytochrome P450 inhibition potential of methylenedioxy-derived designer drugs studied with a two-cocktail approach. Arch Toxicol 90:305–318PubMedCrossRefGoogle Scholar
  105. 105.
    Novellas J, López-Arnau R, Carbó ML, Pubill D, Camarasa J, Escubedo E (2015) Concentrations of MDPV in rat striatum correlate with the psychostimulant effect. J Psychopharmacol 29:1209–1218PubMedCrossRefGoogle Scholar
  106. 106.
    Schindler CW, Thorndike EB, Blough BE, Tella SR, Goldberg SR, Baumann MH (2014) Effects of 3,4-methylenedioxymethamphetamine (MDMA) and its main metabolites on cardiovascular function in conscious rats. Br J Pharmacol 171:83–91PubMedCrossRefGoogle Scholar
  107. 107.
    Crespi C (2016) Flakka-induced prolonged psychosis. Case Rep Psychiatry 2016:3460849PubMedPubMedCentralGoogle Scholar
  108. 108.
    Sykutera M, Cychowska M, Bloch-Boguslawska E (2015) A fatal case of pentedrone and α-pyrrolidinovalerophenone poisoning. J Anal Toxicol 39:324–329PubMedCrossRefGoogle Scholar
  109. 109.
    Rickli A, Hoener MC, Liechti ME (2015) Monoamine transporter and receptor interaction profiles of novel psychoactive substances: para-halogenated amphetamines and pyrovalerone cathinones. Eur Neuropsychopharmacol 25:365–376PubMedCrossRefGoogle Scholar
  110. 110.
    Kolanos R, Sakloth F, Jain AD, Partilla JS, Baumann MH, Glennon RA (2015) Structural modification of the designer stimulant α-pyrrolidinovalerophenone (α-PVP) influences potency at dopamine transporters. ACS Chem Neurosci 6:1726–1731PubMedPubMedCentralCrossRefGoogle Scholar
  111. 111.
    Kaizaki A, Tanaka S, Numazawa S (2014) New recreational drug 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone (alpha-PVP) activates central nervous system via dopaminergic neuron. J Toxicol Sci 39:1–6Google Scholar
  112. 112.
    Aarde SM, Creehan KM, Vandewater SA, Dickerson TJ, Taffe MA (2015) In vivo potency and efficacy of the cathinone α-pyrrolidinopentiophenone and 3,4-methylenedioxypyrovalerone: self-administration and locomotor stimulation in male rats. Psychopharmacology (Berl) 232:3045–3055PubMedCentralCrossRefGoogle Scholar
  113. 113.
    Gatch MB, Dolan SB, Forster MJ (2015) Comparative behavioral pharmacology of three pyrrolidine-containing synthetic cathinone derivatives. J Pharmacol Exp Ther 354:103–110PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2016

Authors and Affiliations

  • Michael H. Baumann
    • 1
  • Mohammad O. Bukhari
    • 1
  • Kurt R. Lehner
    • 1
  • Sebastien Anizan
    • 2
  • Kenner C. Rice
    • 3
  • Marta Concheiro
    • 2
    • 4
  • Marilyn A. Huestis
    • 2
  1. 1.Designer Drug Research Unit of the Intramural Research ProgramNational Institute on Drug Abuse (NIDA), National Institutes of HealthBaltimoreUSA
  2. 2.Chemistry and Drug Metabolism Section of the Intramural Research ProgramNational Institute on Drug Abuse (NIDA), National Institutes of HealthBaltimoreUSA
  3. 3.Drug Design and Synthesis Section of the Intramural Research ProgramNational Institute on Drug Abuse (NIDA), National Institutes of HealthBaltimoreUSA
  4. 4.Department of Sciences, John Jay College of Criminal JusticeCity University of New YorkNew YorkUSA

Personalised recommendations